Opinion
Video
Cara Chang, PharmD, BCOP, examines the prevalence of EGFR positivity, provides an overview of clinically relevant EGFR mutations, and discusses therapeutic options for EGFR-positive mutations.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer